FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to immunology and can be used for differential diagnosis of primary and secondary immune response to measles virus. It is ensured by separation of types of immune response into primary and secondary by limit criteria, based on calculated using ROC analysis for IgG1 and IgG3 subclasses. Determination of amount of specific measles antibodies, relating to subclasses IgG1 and IgG3, is carried out using ELISA analysis. If limit values for IgG1<45.42 % and for IgG3>42 % are obtained of total amount of measles IgG antibodies primary immune response is diagnosed. If limit values for IgG1>45.42 % and for IgG3<42 % are obtained of total amount of measles IgG antibodies primary immune response is diagnosed.
EFFECT: use of given method enables control of measles immunity quality and diagnosis of cases of primary and secondary vaccinal failures.
1 cl, 3 tbl, 2 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DIFFERENTIAL DIAGNOSIS OF PRIMARY AND SECONDARY IMMUNE RESPONSE TO RUBELLA VIRUS | 2015 |
|
RU2585246C1 |
METHOD FOR DIFFERENTIAL DIAGNOSIS OF PRIMARY AND SECONDARY IMMUNE RESPONSE TO EPIDEMIC PAROTITIS VIRUS | 2015 |
|
RU2599504C1 |
METHOD FOR PREDICTION OF PRIMARY AND SECONDARY VACCINAL FAILURES AT VACCINATION AGAINST VIRUSES OF RUBEOLA, RUBELLA AND EPIDEMIC HEPATITIS IN CHILDREN USING PRIORIX VACCINE AND METHOD OF INDIVIDUAL APPROACH TO CORRECTION OF VACCINAL FAILURES | 2015 |
|
RU2599506C1 |
METHOD FOR DETERMINING AND QUANTIFYING SPECIFIC CELLULAR IMMUNITY TO SARS-CoV-2 VIRUS S-PROTEIN ANTIGENS | 2021 |
|
RU2762616C1 |
METHOD FOR DETERMINING NEED FOR REVACCINATION AGAINST MEASLES IN MEDICAL WORKERS | 2020 |
|
RU2752144C1 |
METHOD FOR DETERMINING AND QUANTIFYING SPECIFIC CELLULAR IMMUNITY TO N-PROTEIN ANTIGENS OF SARS-CoV-2 VIRUS | 2023 |
|
RU2818080C1 |
0 |
|
SU1784098A3 | |
METHOD FOR PREVENTING COMPLICATIONS CAUSED BY VACCINATION OF CHILDREN SUFFERING FROM RECURRENT HERPETIC INFECTION | 2003 |
|
RU2228756C1 |
METHOD FOR PROPHYLAXIS OF POST-VACCINAL COMPLICATIONS | 2006 |
|
RU2316343C2 |
METHOD FOR DETERMINING COMPLEMENT-ACTIVATING FUNCTION OF SARS-CoV-2 ANTIBODIES FOR PREDICTING SEVERITY OF COVID-19 | 2023 |
|
RU2818351C1 |
Authors
Dates
2016-12-20—Published
2015-06-15—Filed